echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Suppress inflammation and fibrosis FDA approves the first ROCK2 inhibitor

    Suppress inflammation and fibrosis FDA approves the first ROCK2 inhibitor

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Kadmon announced that the US FDA approved the company's Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) patients over 12 years of age who have received two pre-systemic treatments


    Hematopoietic stem cell transplantation is a common treatment for blood or bone marrow cancer


    As a ROCK2 kinase inhibitor, belumosudil can reduce the phosphorylation of STAT3 and strengthen the phosphorylation of STAT5, thereby down-regulating over-activated T helper cells (Th17) and enhancing the function of regulatory T cells (Treg), thereby rebuilding immune balance


    ▲Illustration of the mechanism of action of Belumosudil (picture source: reference [2])

    The FDA approval is based on the results of a random, open-label, multi-center pivotal clinical trial called ROCKstar


    "Rezurock is a new treatment model for thousands of cGVHD patients


    Reference materials:

    [1] US FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD).


    [2] Kadmon Corporate Presentation.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.